{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:40:25Z","timestamp":1793133625366,"version":"4.5.0"},"reference-count":104,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.02965","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T05:47:55Z","timestamp":1576561675000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":435,"title":["The Intriguing History of Cancer Immunotherapy"],"prefix":"10.3389","volume":"10","author":[{"given":"Paula","family":"Dobosz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Dzieci\u0105tkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,12,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3389\/fimmu.2017.00829","article-title":"Cancer immunotherapy: historical perspective of a clinical revolution and emerging preclinical animal models","volume":"8","author":"Decker","year":"2017","journal-title":"Front Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.20506\/rst.26.1.1724","article-title":"A brief history of vaccines and vaccination","volume":"26","author":"Lombard","year":"2007","journal-title":"Rev Sci Tech."},{"key":"B3","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-70622-1","article-title":"The Basics of Cancer Immunotherapy","author":"Dong","year":"2018"},{"key":"B4","doi-asserted-by":"publisher","first-page":"250","DOI":"10.20517\/2394-4722.2017.41","article-title":"Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead","volume":"3","author":"Oiseth","year":"2017","journal-title":"J Cancer Metastasis Treat."},{"key":"B5","article-title":"Viruses and Human Cancers","year":"2019"},{"key":"B6","unstructured":"A Brief History of Immunotherapy309097052014"},{"key":"B7","first-page":"154","article-title":"The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas","volume":"26","author":"McCarthy","year":"2006","journal-title":"Iowa Orthop. J."},{"key":"B8","unstructured":"2019"},{"key":"B9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cytogfr.2009.07.004","article-title":"Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited","volume":"20","author":"Decker","year":"2009","journal-title":"Cytok Growth Factor Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1098\/rspb.1957.0048","article-title":"Virus interference. I. The interferon","volume":"147","author":"Isaacs","year":"1957","journal-title":"Proc R Soc Lond Ser B Biol Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/214992a0","article-title":"Cellular basis of the immunological defects in thymectomized mice","volume":"214","author":"Miller","year":"1967","journal-title":"Nature."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1084\/jem.137.5.1142","article-title":"Identification of a Novel Cell Type in Peripheral Lymphoid Organs of Mice: I. Morphology, quantitation, tissue distribution","volume":"137","author":"Steinman","year":"1973","journal-title":"J Exp Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/eji.1830050208","article-title":"Natural killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype","volume":"5","author":"Kiessling","year":"1975","journal-title":"Eur J Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/eji.1830050209","article-title":"Natural killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell","volume":"5","author":"Kiessling","year":"1975","journal-title":"Eur J Immunol."},{"key":"B15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1634\/theoncologist.1-3-159","article-title":"Bone marrow transplantation for cancer: an overview","volume":"1","author":"Pavletic","year":"1996","journal-title":"Oncologist."},{"key":"B16","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1126\/science.40.1042.904","article-title":"A Possible mendelian explanation for a type of inheritance apparently non-mendelian in nature","volume":"40","author":"Little","year":"1914","journal-title":"Science."},{"key":"B17","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/scientificamerican0577-62","article-title":"Cancer Immunology","volume":"236","author":"Old","year":"1977","journal-title":"Sci Am."},{"key":"B18","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1073\/pnas.1.7.435","article-title":"The lymphocyte as a factor in natural and induced resistance to transplanted cancer","volume":"1","author":"Murphy","year":"1915","journal-title":"Proc Natl Acad Sci USA."},{"key":"B19","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/184291a0","article-title":"Effect of Bacillus Calmette-Gu\u00e9rin infection on transplanted tumours in the mouse","volume":"184","author":"Old","year":"1957","journal-title":"Nature."},{"key":"B21","unstructured":"Cancer Vaccines and Immunotherapy2018"},{"key":"B22","article-title":"How the Immune System Works","author":"Sompayrac","year":"2016"},{"key":"B23","doi-asserted-by":"publisher","first-page":"19976","DOI":"10.18632\/oncotarget.5116","article-title":"Going viral: a review of replication-selective oncolytic adenoviruses","volume":"6","author":"Larson","year":"2015","journal-title":"Oncotarget."},{"key":"B24","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat. Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1126\/science.183.4124.534","article-title":"Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice","volume":"183","author":"Stutman","year":"1974","journal-title":"Science."},{"key":"B26","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/253142a0","article-title":"Delayed tumour appearance and absence of regression in nude mice infected with murine sarcoma virus","volume":"253","author":"Stutman","year":"1979","journal-title":"Nature."},{"key":"B27","first-page":"353","article-title":"Chemical carcinogenesis in nude mice: comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose","volume":"62","author":"Stutman","year":"1979","journal-title":"J Natl Cancer Inst."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.3389\/fimmu.2018.01869","article-title":"Natural killer cells: development, maturation, and clinical utilization","volume":"9","author":"Malarkannan","year":"2018","journal-title":"Front Immunol."},{"key":"B29","first-page":"226","article-title":"Cytotoxic lymphocytes from normal donors. A functional marker of human non-T lymphocytes","volume":"21","author":"Pross","year":"1975","journal-title":"Clin Exp Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/35074122","article-title":"IFN\u03b3 and lymphocytes prevent primary tumour development and shape tumour immunogenicity","volume":"410","author":"Shankaran","year":"2001","journal-title":"Nature."},{"key":"B31","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","article-title":"The three Es of cancer immunoediting","volume":"22","author":"Dunn","year":"2004","journal-title":"Annu Rev Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000386035","article-title":"The concept of immunological surveillance","volume":"13","author":"Burnet","year":"1970","journal-title":"Prog Exp Tumor Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1126\/science.1840703","article-title":"A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma","volume":"254","author":"van der Bruggen","year":"1991","journal-title":"Science."},{"key":"B35","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1365-3083.1984.tb00931.x","article-title":"Origin of the terms \u2018antibody' and 'antigen","volume":"19","author":"Lindenmann","year":"1984","journal-title":"Scand J Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.micinf.2004.04.003","article-title":"Paul Ehrlich \u2014 in search of the magic bullet","volume":"6","author":"Winau","year":"2004","journal-title":"Microbes Infect."},{"key":"B37","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/(SICI)1521-1878(199911)21:11<966::AID-BIES9>3.0.CO;2-Z","article-title":"The hybridoma revolution : an offshoot of basic research","volume":"21","author":"Milstein","year":"1999","journal-title":"Bioessays."},{"key":"B38","doi-asserted-by":"publisher","first-page":"4694","DOI":"10.1182\/blood-2013-02-482570","article-title":"Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell \u2013 mediated antibody-dependent cellular cytotoxicity","volume":"121","author":"Rudnicka","year":"2019","journal-title":"Blood."},{"key":"B39","doi-asserted-by":"publisher","first-page":"122","DOI":"10.5483\/BMBRep.2014.47.3.283","article-title":"4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy","volume":"47","author":"Vinay","year":"2014","journal-title":"BMB Rep."},{"key":"B40","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nm0697-682","article-title":"Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors","volume":"3","author":"Melero","year":"1997","journal-title":"Nat Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1158\/1535-7163.MCT-11-0677","article-title":"Immunotherapy of cancer with 4-1BB","volume":"11","author":"Vinay","year":"2012","journal-title":"Mol Cancer Ther."},{"key":"B42","article-title":"ASCO Daily News: History of Immunotherapy in Solid Tumours","year":"2018"},{"key":"B43","first-page":"2293","article-title":"Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody. J Immunol","volume":"129","author":"Allison","year":"1982"},{"key":"B44","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/0092-8674(83)90232-5","article-title":"The major histocompatibility complex-restricted antigen receptor on T cells in mouse and man: Identification of constant and variable peptides","volume":"35","author":"Kappler","year":"1983","journal-title":"Cell."},{"key":"B45","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/328267a0","article-title":"A new member of the immunoglobulin superfamily\u2014CTLA-4","volume":"328","author":"Brunet","year":"1987","journal-title":"Nature."},{"key":"B46","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1084\/jem.182.2.459","article-title":"CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation","volume":"182","author":"Krummel","year":"1995","journal-title":"J Exp Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science."},{"key":"B48","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1200\/jco.2014.32.15_suppl.5011","article-title":"Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC)","volume":"32","author":"Powles","year":"2014","journal-title":"J Clin Oncol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1200\/jco.2013.31.15_suppl.3000","article-title":"A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors","volume":"31","author":"Herbst","year":"2013","journal-title":"J Clin Oncol."},{"key":"B50","unstructured":"Roche Scores First U.S. Approval of Immunotherapy for Breast Cancer BegleyS 2019"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1126\/science.181845","article-title":"Selective in vitro growth of T lymphocytes from normal human bone marrows","volume":"193","author":"Morgan","year":"1976","journal-title":"Science."},{"key":"B52","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/302305a0","article-title":"Structure and expression of a cloned cDNA for human interleukin-2","volume":"302","author":"Taniguchi","year":"1983","journal-title":"Nature."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1126\/science.6367046","article-title":"Biological activity of recombinant human interleukin-2 produced in Escherichia coli","volume":"223","author":"Rosenberg","year":"1984","journal-title":"Science."},{"key":"B54","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J Immunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","article-title":"Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer","volume":"313","author":"Rosenberg","year":"1985","journal-title":"N Engl J Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N Engl J Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.adro.2018.08.018","article-title":"Role of the immunosuppressive microenvironment in immunotherapy","volume":"3","author":"Tormoen","year":"2018","journal-title":"Adv Radiat Oncol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nrc1586","article-title":"Immunosuppressive networks in the tumour environment and their therapeutic relevance","volume":"5","author":"Zou","year":"2005","journal-title":"Nat Rev Cancer."},{"key":"B59","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1182\/blood-2006-07-035972","article-title":"Inhibitory effect of tumor cell\u2013derived lactic acid on human T cells","volume":"109","author":"Fischer","year":"2007","journal-title":"Blood."},{"key":"B60","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ccell.2018.03.008","article-title":"The immune revolution: a case for priming, not checkpoint","volume":"33","author":"Vonderheide","year":"2018","journal-title":"Cancer Cell."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1182\/blood.V99.7.2468","article-title":"CD4+ and CD8+ anergic T cells induced by interleukin-10\u2013treated human dendritic cells display antigen-specific suppressor activity","volume":"99","author":"Steinbrink","year":"2002","journal-title":"Blood."},{"key":"B62","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1073\/pnas.1117736109","article-title":"Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase","volume":"109","author":"Ravishankar","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B63","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2174\/1568009616888151112095948","article-title":"Cytochrome P450 2W1 (CYP2W1) in Colorectal Cancers","volume":"16","author":"Chung","year":"2015","journal-title":"Curr Cancer Drug Targets."},{"key":"B64","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13046-019-1153-8","article-title":"Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment","volume":"38","author":"Looi","year":"2019","journal-title":"J Exp Clin Cancer Res."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2174\/1389450117666161216125344","article-title":"Targeting legumain as a novel therapeutic strategy in cancers","volume":"18","author":"Mai","year":"2017","journal-title":"Curr Drug Targets"},{"key":"B66","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1001\/archotol.1975.00780400025007","article-title":"Immunosuppression and cancer: importance in head and neck surgery","volume":"101","author":"Penn","year":"1975","journal-title":"Arch Otolaryngol. Head Neck Surg."},{"key":"B67","doi-asserted-by":"publisher","first-page":"e26961","DOI":"10.4161\/onci.26961","article-title":"Immunosuppressants in cancer prevention and therapy","volume":"2","author":"Blagosklonny","year":"2013","journal-title":"Oncoimmunology."},{"key":"B68","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases","volume":"155","author":"Sakaguchi","year":"1995","journal-title":"J Immunol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1172\/JCI69999","article-title":"Targeting immunosuppression for cancer therapy","volume":"123","author":"Ghirelli","year":"2013","journal-title":"J Clin Invest."},{"key":"B70","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1200\/JCO.2005.12.172","article-title":"Tumor-associated macrophages: the double-edged sword in cancer progression","volume":"23","author":"Chen","year":"2005","journal-title":"J Clin Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1158\/0008-5472.CAN-12-3981","article-title":"CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer","volume":"73","author":"Xu","year":"2013","journal-title":"Cancer Res."},{"key":"B72","unstructured":"What are Cancer Vaccines?31767927Cancer.Net.2018"},{"key":"B73","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.cell.2012.03.007","article-title":"Cancer and the immune system","volume":"149","author":"Hosking","year":"2012","journal-title":"Cell."},{"key":"B74","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.4049\/jimmunol.178.5.2615","article-title":"Human tumor immunology at the molecular divide","volume":"178","author":"Finn","year":"2007","journal-title":"J Immunol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med."},{"key":"B76","doi-asserted-by":"publisher","first-page":"4354","DOI":"10.1002\/cncr.26734","article-title":"HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ","volume":"118","author":"Sharma","year":"2012","journal-title":"Cancer."},{"key":"B77","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3389\/fphar.2016.00356","article-title":"Restoring lost anti-HER-2 Th1 immunity in breast cancer: a crucial role for Th1 cytokines in therapy and prevention","volume":"7","author":"Nocera","year":"2016","journal-title":"Front Pharmacol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1007\/s00262-008-0536-z","article-title":"Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines","volume":"57","author":"de Gruijl","year":"2008","journal-title":"Cancer Immunol Immunother."},{"key":"B79","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1097\/CJI.0b013e3180de4ce8","article-title":"Phase I\/II study of vaccination with electrofused allogeneic dendritic cells\/autologous tumor-derived cells in patients with stage IV renal cell carcinoma","volume":"30","author":"Avigan","year":"2007","journal-title":"J Immunother."},{"key":"B80","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1126\/science.356.6334.122","article-title":"Personalized tumor vaccines keep cancer in check","volume":"356","author":"Kaiser","year":"2017","journal-title":"Science."},{"key":"B81","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12943-019-1055-6","article-title":"Neoantigen vaccine: an emerging tumor immunotherapy","volume":"18","author":"Peng","year":"2019","journal-title":"Mol Cancer."},{"key":"B82","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.smim.2015.11.002","article-title":"Cancer immunotherapy targeting neoantigens","volume":"28","author":"Lu","year":"2016","journal-title":"Semin Immunol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.3389\/fimmu.2019.01856","article-title":"Mutation-derived neoantigens for cancer immunotherapy","volume":"10","author":"Castle","year":"2019","journal-title":"Front Immunol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13045-019-0787-5","article-title":"Tumor neoantigens: from basic research to clinical applications","volume":"12","author":"Jiang","year":"2019","journal-title":"J Hematol Oncol."},{"key":"B85","article-title":"The History of Oncology","author":"Wagener","year":"2009"},{"key":"B86","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1245\/s10434-018-6658-4","article-title":"An Update on immunotherapy for solid tumors: a review","volume":"25","author":"Pham","year":"2018","journal-title":"Ann Surg Oncol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci USA."},{"key":"B88","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/978-3-540-73259-4_14","article-title":"The T-Body approach: redirecting T cells with antibody specificity","volume":"181","author":"Eshhar","year":"2008"},{"key":"B89","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"B90","unstructured":"CAR T-Cell Therapy Approved for Some Children and Young Adults with Leukemia2017"},{"key":"B91","unstructured":"FDA Approves Second CAR T-Cell Therapy for Lymphoma2018"},{"key":"B92","unstructured":"With FDA Approval for Advanced Lymphoma, Second CAR T-Cell Therapy Moves to the Clinic2018"},{"key":"B93","unstructured":"FDA Approval Brings First Gene Therapy to the United States2017"},{"key":"B94","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.humimm.2018.09.007","article-title":"CRISPR\/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment","volume":"79","author":"Mollanoori","year":"2018","journal-title":"Hum Immunol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1080\/21645515.2019.1571893","article-title":"CRISPR\/Cas9-based genome editing in the era of CAR T cell immunotherapy","volume":"15","author":"Salas-Mckee","year":"2019","journal-title":"Hum Vaccin Immunother."},{"key":"B96","doi-asserted-by":"publisher","first-page":"eaau4292","DOI":"10.1126\/sciimmunol.aau4292","article-title":"Direct reprogramming of fibroblasts into antigen-presenting dendritic cells","volume":"3","author":"Rosa","year":"2018","journal-title":"Sci Immunol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"15121","DOI":"10.1073\/pnas.96.26.15121","article-title":"The onset and extent of genomic instability in sporadic colorectal tumor progression","volume":"96","author":"Stoler","year":"1999","journal-title":"Proc Natl Acad Sci USA."},{"key":"B98","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/ijc.25270","article-title":"\u2018Hard' and \u2018soft' lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy","volume":"127","author":"Garrido","year":"2010","journal-title":"Int J Cancer."},{"key":"B99","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.coi.2015.12.007","article-title":"The urgent need to recover MHC class I in cancers for effective immunotherapy","volume":"39","author":"Garrido","year":"2016","journal-title":"Curr Opin Immunol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti\u2013PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science."},{"key":"B101","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.ccell.2018.03.015","article-title":"The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy","volume":"33","author":"Gopalakrishnan","year":"2018","journal-title":"Cancer Cell."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1038\/s41591-018-0238-9","article-title":"Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis","volume":"24","author":"Wang","year":"2018","journal-title":"Nat Med."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2018.3676","article-title":"Hyperprogressive disease in patients with advanced non\u2013small cell lung cancer treated with PD-1\/PD-L1 inhibitors or with single-agent chemotherapy","volume":"14","author":"Ferrara","year":"2018","journal-title":"JAMA Oncol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02965\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T03:20:31Z","timestamp":1695525631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02965\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,17]]},"references-count":104,"alternative-id":["10.3389\/fimmu.2019.02965"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.02965","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,17]]},"article-number":"2965"}}